Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
313 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Overview 11 Pipeline Products for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis 12 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Development by Companies 13 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 17 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Development by Companies 21 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Products under Investigation by Universities/Institutes 24 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Companies Involved in Therapeutics Development 25 Johnson & Johnson 25 Sanofi 26 AstraZeneca PLC 27 Eli Lilly and Company 28 Viralytics Ltd. 29 Genentech, Inc. 30 Bavarian Nordic A/S 31 Emergent BioSolutions Inc. 32 Takeda Pharmaceutical Company Limited 33 Millennium Pharmaceuticals, Inc. 34 Novartis AG 35 GTx, Inc. 36 Ono Pharmaceutical Co., Ltd. 37 Teva Pharmaceutical Industries Limited 38 Progenics Pharmaceuticals, Inc. 39 Exelixis, Inc. 40 Celgene Corporation 41 Onyx Pharmaceuticals, Inc. 42 Merck KGaA 43 Active Biotech AB 44 Oncolytics Biotech Inc. 45 Medivation, Inc. 46 Synta Pharmaceuticals Corp. 47 Supratek Pharma Inc. 48 CellCentric Ltd. 49 CureVac GmbH 50 GenSpera, Inc. 51 BIND Therapeutics, Inc. 52 NewLink Genetics Corporation 53 Bellicum Pharmaceuticals, Inc. 54 AB Science 55 Adamis Pharmaceuticals Corporation 56 Karyopharm Therapeutics, Inc. 57 ATLAB Pharma SAS 58 AbbVie Inc. 59 Sotio a.s. 60 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Target 62 Assessment by Mechanism of Action 67 Assessment by Route of Administration 71 Assessment by Molecule Type 73 Drug Profiles 75 custirsen sodium - Drug Profile 75 tasquinimod - Drug Profile 78 enzalutamide - Drug Profile 80 cabozantinib s-malate - Drug Profile 83 rilimogene galvacirepvec - Drug Profile 86 masitinib - Drug Profile 88 cabazitaxel - Drug Profile 91 DCVAC/PCa - Drug Profile 93 patupilone - Drug Profile 95 abituzumab - Drug Profile 97 olaratumab - Drug Profile 99 navitoclax - Drug Profile 101 vandetanib - Drug Profile 103 PSMA ADC - Drug Profile 109 GTx-758 - Drug Profile 111 olaparib - Drug Profile 112 carfilzomib - Drug Profile 115 ganetespib - Drug Profile 119 pelareorep - Drug Profile 123 MLN-0128 - Drug Profile 127 dovitinib lactate - Drug Profile 129 CV-9103 - Drug Profile 132 G-202 - Drug Profile 134 docetaxel nanoparticles - Drug Profile 136 indoximod - Drug Profile 138 Adenovirus/PSA Vaccine - Drug Profile 140 CreaVax-PC - Drug Profile 141 TL-118 - Drug Profile 142 selinexor - Drug Profile 144 CV-9104 - Drug Profile 146 Dendritic Cell Therapy Targeting PSA, PAP, Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 147 ATL-101 - Drug Profile 148 Cell Therapy to Inhibit PSMA for Metastatic Hormone Refractory Prostate Cancer - Drug Profile 150 TRC-105 - Drug Profile 151 AZD-5363 - Drug Profile 154 BPX-101 - Drug Profile 156 CC-115 - Drug Profile 158 CFG-920 - Drug Profile 159 Osteodex - Drug Profile 160 CVA-21 - Drug Profile 161 erismodegib - Drug Profile 165 nivolumab - Drug Profile 168 JNJ-56021927 - Drug Profile 172 RG-7450 - Drug Profile 174 AZD-5312 - Drug Profile 175 BPX-201 - Drug Profile 176 ONC-1-13B - Drug Profile 177 APC-200 - Drug Profile 178 APC-300 - Drug Profile 180 ES-414 - Drug Profile 181 Small Molecules to Inhibit Deubiquitinase for Castrate Resistant Prostate Cancer - Drug Profile 182 cabazitaxel nanoformulation - Drug Profile 183 Small Molecule To Antagonize Androgen Receptor For Prostate Cancer - Drug Profile 184 Small Molecules to Inhibit Bromodomain for Cancer - Drug Profile 185 Protein for Prostate Cancer - Drug Profile 186 Monoclonal Antibodies to Inhibit N-Cadherin for Bladder and Metastatic Hormone Refractory Prostate Cancers - Drug Profile 187 ABS-001 - Drug Profile 188 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Recent Pipeline Updates 189 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects 297 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products 298 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Product Development Milestones 299 Featured News & Press Releases 299 Appendix 308 Methodology 308 Coverage 308 Secondary Research 308 Primary Research 308 Expert Panel Validation 308 Contact Us 309 Disclaimer 309
List of Tables Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, H2 2014 15 Number of Products under Development for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Comparative Analysis, H2 2014 16 Number of Products under Development by Companies, H2 2014 18 Number of Products under Development by Companies, H2 2014 (Contd..1) 19 Number of Products under Development by Companies, H2 2014 (Contd..2) 20 Number of Products under Investigation by Universities/Institutes, H2 2014 21 Comparative Analysis by Late Stage Development, H2 2014 22 Comparative Analysis by Clinical Stage Development, H2 2014 23 Comparative Analysis by Early Stage Development, H2 2014 24 Products under Development by Companies, H2 2014 25 Products under Development by Companies, H2 2014 (Contd..1) 26 Products under Development by Companies, H2 2014 (Contd..2) 27 Products under Investigation by Universities/Institutes, H2 2014 28 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Johnson & Johnson, H2 2014 29 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sanofi, H2 2014 30 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AstraZeneca PLC, H2 2014 31 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2014 32 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Viralytics Ltd., H2 2014 33 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Genentech, Inc., H2 2014 34 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 35 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H2 2014 36 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 37 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 38 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Novartis AG, H2 2014 39 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GTx, Inc., H2 2014 40 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 41 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 42 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 43 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Exelixis, Inc., H2 2014 44 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Celgene Corporation., H2 2014 45 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 46 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Merck KGaA, H2 2014 47 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Active Biotech AB, H2 2014 48 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 49 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Medivation, Inc., H2 2014 50 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 51 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Supratek Pharma Inc., H2 2014 52 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CellCentric Ltd., H2 2014 53 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by CureVac GmbH, H2 2014 54 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by GenSpera, Inc., H2 2014 55 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by BIND Therapeutics, Inc., H2 2014 56 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by NewLink Genetics Corporation, H2 2014 57 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2014 58 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AB Science, H2 2014 59 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 60 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 61 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by ATLAB Pharma SAS, H2 2014 62 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by AbbVie Inc., H2 2014 63 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Pipeline by Sotio a.s., H2 2014 64 Assessment by Monotherapy Products, H2 2014 65 Number of Products by Stage and Target, H2 2014 68 Number of Products by Stage and Mechanism of Action, H2 2014 73 Number of Products by Stage and Route of Administration, H2 2014 76 Number of Products by Stage and Molecule Type, H2 2014 78 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2014 193 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Dormant Projects, H2 2014 301 Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer - Discontinued Products, H2 2014 302
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
